vTv Therapeutics, Inc. Class A VTVT 深 沪
已收盘 02-06 16:00:00 美东时间
29.02
-1.990
-6.42%
华盛通- 最 高33.035
- 今 开31.11
- 成交量 2.62万股
- 最 低 28.84
- 昨 收 31.01
- 总市值 1.14亿
- 52周最高 44.00
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 14.00
- 委 比 -36.05%
- 总股本 393.83万
- 历史最高 560.00
- 量 比 0.79
- 振 幅 13.53%
- 历史最低 7.38
- 每 手 1
- 风险率 7.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多vTv Therapeutics Expands License Deal With Newsoara Biopharma To Offer Global Rights To PDE4 Inhibitor
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the
02-02 21:23
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics and Newsoara Biopharma expanded their partnership, granting Newsoara global rights to develop and commercialize HPP737, a PDE4 inhibitor. vTv received a $20 million upfront payment, with additional milestones and royalties. The collaboration aims to advance HPP737 for treating inflammation-mediated diseases, leveraging its potential to overcome common side effects of existing PDE4 inhibitors. HPP737 has shown promise in preclinic...
02-02 13:00
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Roth Capital Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $58
Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $58.
01-23 17:48
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
TD Cowen Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $67
TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $67.
01-05 20:48
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
vTv Therapeutics And M42's IROS Submits Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health; This Study Constitutes The Longest Trial Investigating Cadisegliatin To Date
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42's Insights Research Organization & Solutions (IROS),
2025-12-19 05:10
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
